Evidence map›Paper›PMID 37627056›Full record

ArticleCancers2023

Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM).

Marion Detroit, Mathis Collier, Nathanaël Beeker, Lise Willems, Justine Decroocq, Bénédicte Deau-Fischer, Marguerite Vignon, Rudy Birsen, Frederique Moufle, Clément Leclaire and 15 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05450367 (Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy.), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05450367 completednot on this map

Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy.

TypeobservationalSponsorAssistance Publique - Hôpitaux de ParisRan2017 to 2022Enrolled249ConditionsBlood CancerArmsData collection
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 1 country.

Marion DetroitPharmacy Department, Pitié-Salpêtrière Hospital, Greater Paris University Hospitals (AP-HP), Sorbonne University, 75013 Paris, France.
Mathis CollierClinical Research Unit, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Nathanaël BeekerClinical Research Unit, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France.ORCID 0000-0002-2828-1356
Lise WillemsHematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Justine DecroocqHematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Bénédicte Deau-FischerHematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France.ORCID 0000-0002-7468-5466
Marguerite VignonHematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Rudy BirsenHematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Frederique MoufleAdult Department, Hospital at Home, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Clément LeclaireAdult Department, Hospital at Home, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Elisabeth BalladurAdult Department, Hospital at Home, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Paul DeschampsHematology Oncology Department, André Mignot Hospital, 78157 Le Chesnay, France.
Adrien ChauchetHematology Department, University Hospital of Besançon, 25000 Besançon, France.
Rui BatistaPharmacy Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France.ORCID 0000-0002-9273-3644
Samuel LimatPharmacy Department, University Hospital of Besançon, 25000 Besançon, France.
Jean-Marc TreluyerClinical Research Unit, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Laure RicardHematology Department, Saint Antoine Hospital, AP-HP, INSERM UMRs 938, Sorbonne University, 75012 Paris, France.ORCID 0000-0003-4416-3285
Nicolas StockerHematology Department, Saint Antoine Hospital, AP-HP, INSERM UMRs 938, Sorbonne University, 75012 Paris, France.ORCID 0000-0001-7316-5832
Olivier HermineHematology Department, Necker Hospital, AP-HP, Centre Paris-Cité University, 75015 Paris, France.
Sylvain ChoquetHematology Department, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, 75013 Paris, France.
Véronique MorelHematology Department, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, 75013 Paris, France.
Carole MetzPharmacy Department, Pitié-Salpêtrière Hospital, Greater Paris University Hospitals (AP-HP), Sorbonne University, 75013 Paris, France.
Didier BouscaryHematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Marie KroemerPharmacy Department, University Hospital of Besançon, 25000 Besançon, France.
Jérémie ZerbitCancer Treatment Unit, Pharmacy Department, Hospital at Home, AP-HP, Centre Paris-Cité University, 75014 Paris, France.
Université Paris Cité · FRInserm · FRSorbonne Université · FRCentre Hospitalier Universitaire de Besançon · FRDélégation Paris 5 · FRHôpital André Mignot · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy (IT) is a major therapeutic strategy for lymphoma, significantly improving patient prognosis. IT remains ineffective for a significant number of patients, however, and exposes them to specific toxicities. The identification predictive factors around efficacy and toxicity would allow better targeting of patients with a higher ratio of benefit to risk. PRONOSTIM is a multicenter and retrospective study using the Clinical Data Warehouse (CDW) of the Greater Paris University Hospitals network. Adult patients with Hodgkin lymphoma or diffuse large-cell B lymphoma treated with immune checkpoint inhibitors or CAR T (Chimeric antigen receptor T) cells between 2017 and 2022 were included. Analysis of covariates influencing progression-free survival (PFS) or the occurrence of grade ≥3 toxicity was performed. In total, 249 patients were included. From this study, already known predictors for response or toxicity of CAR T cells such as age, elevated lactate dehydrogenase, and elevated C-Reactive Protein at the time of infusion were confirmed. In addition, male gender, low hemoglobin, and hypo- or hyperkalemia were demonstrated to be potential predictive factors for progression after CAR T cell therapy. These findings prove the attractiveness of CDW in generating real-world data, and show its essential contribution to identifying new predictors for decision support before starting IT.

Indexed as

clinical data warehouselymphomapredictive factors of immunotherapyreal-world data

Identifiers

PMID37627056
PMCPMC10452259
OpenAlexW4385708383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.